%0 Journal Article
%T 长链非编码RNA在乳腺癌中的研究进展<br>Research Progress of Long Noncoding RNA in Breast Cancer
%A 郑欣
%A 刘杰
%A 宋鹏霞
%A 姚水洪
%A 罗烨
%J World Journal of Cancer Research
%P 52-60
%@ 2164-9057
%D 2022
%I Hans Publishing
%R 10.12677/WJCR.2022.122007
%X 乳腺癌是异质性的恶性肿瘤，发病率位居全球女性恶性肿瘤之首，传统的治疗手段如手术切除和放化疗的作用较为有限，而分子靶向治疗作为乳腺癌的新型治疗手段，具有效率高、特异性强和副作用小等优点。长链非编码RNA (long noncoding RNA, lncRNA)是一类长度大于200 nt且无蛋白编码功能的转录本，其参与细胞的多个生物学进程，进而在多种生理病理活动中起到关键调控的作用。随着高通量测序技术的发展，现已发现多种lncRNA在乳腺癌中异常表达，其与乳腺癌的发生、发展、转移以及耐药均密切相关，有望作为乳腺癌诊断、预后和治疗的分子靶标。<br />
As a heterogeneous malignant tumor, female breast cancer has become the most commonly diagnosed cancer worldwide. Conventional treatments such as surgical resection, radiotherapy and chemotherapy are not that useful. Molecular targeted therapy is a new way for breast cancer treatment, with high efficiency, high specificity and less side effects. LncRNA (long noncoding RNA) is a noncoding transcript with lengths over 200 nt. LncRNA modulates various biological functions and participates in a variety of physiological and pathological processes. With the development of transcriptome high-throughput sequencing, it has been found that abnormally expressed LncRNA is associated with occurrence, development, metastasis and drug resistancein breast cancer. lncRNA is expected to act as a molecular target for diagnosis, prognosis and treatment of breast cancer.
%K 乳腺癌，诊断，长链非编码RNA，竞争性内源RNA，耐药，分子靶标<br>Breast Cancer
%K Diagnosis
%K Long Noncoding RNA (lncRNA)
%K Competing Endogenous RNA (ceRNA)
%K Drug Resistance
%K Molecular Target
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=50224